Clinical Trials Logo

Acute Myeloid Leukemia, Adult clinical trials

View clinical trials related to Acute Myeloid Leukemia, Adult.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06285136 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia, Adult

Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult

Start date: March 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This study proposes to conduct a prospective, multicenter, single-arm study to explore the efficacy and safety of venetoclax in combination with high-dose decitabine (DEC3-VEN) in new diagnosed adult patients with AML, and to provide evidence for the optimal selection of clinical treatment regimens, which is planned to be conducted in 10 research centers across the country.

NCT ID: NCT06252584 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia, Adult

Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients

AML-VAC-XS15
Start date: May 2, 2024
Phase: Phase 1
Study type: Interventional

The aim of this Phase I study is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a multi-peptide vaccine adjuvanted with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG (AML-VAC-XS15) in AML patients who have achieved CR or CRi with first line treatment.

NCT ID: NCT06199557 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia, Adult

A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients

HUVAMER
Start date: January 25, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety, tolerability, and preliminary efficacy of the combination treatment of hydroxyurea capsules and valproic acid capsules, or the combination treatment of 6-mercaptopurine tablets and valproic acid capsules in male and female patients aged 18 years or older with acute myeloid leukemia or high- risk myelodysplastic syndrome. The population to be studied is newly diagnosed AML patients who are considered unfit for standard induction chemotherapy, HR-MDS unfit/ineligible for standard treatment, and relapsed/refractory AML/HR-MDS patients who are considered unfit for standard therapy ,or are, for some reason, ineligible for another type of therapy. Clinically, hydroxyurea, valproic acid and 6-mercaptopurine are historically very well-known therapeutic agents with low toxicity profiles. The rationale for this study is that the combination of these drugs with low toxicity will be well tolerated in elderly AML patients with comorbidities, or lower performance status. This combination could have a beneficial therapeutic effect on overall survival and contribute to a better quality of life.

NCT ID: NCT05133882 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia, Adult

A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

Start date: October 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center open clinical study aimed at evaluating the efficacy and safety of Clifutinib Besylate combined with chemotherapy in newly-treated adult subjects with AML